Podcasts about papillomavirus

HPV, das humane Papillomavirus, wird vorwiegend durch Sexualkontakte übertragen. Was dann weiter passiert, hängt auch von den Sexualpraktiken ab, also vaginal, anal und oral. Dementsprechend gibt es auch unterschiedliche Krebs-Manifestationen: Krebs im Urogenitaltrakt, aber es gibt eben auch Analkarzinome und eine zunehmende Anzahl von Krebserkrankungen im Mund-Rachen-Bereich. Das sagt Prof. Dr. Ursula Wiedermann-Schmidt, Leiterin des Instituts für spezifische Prophylaxe und Tropenmedizin an der MedUni Wien. Anlass unseres Treffens war der Welt-HPV-Tag am 4. März. Alles, was an diesem Tag passiert, soll das Bewusstsein für die Bedeutung von Impfungen und Vorsorge im Kampf gegen HPV-bedingte Krebsarten stärken. In Österreich wird die HPV-Impfung kostenlos bis zum vollendeten 30. Lebensjahr angeboten – bis Ende 2025. Idealerweise sollte die Impfung zwischen 9 und 11 Jahren erfolgen. In diesem Alter entwickelt der Körper eine besonders starke Immunantwort, um krebsauslösende HP-Viren unschädlich zu machen. Obwohl HP-Viren Gebärmutterhalskrebs und andere Krebsarten (Scheide, Vulva, Penis, Darmausgang und Mund-Rachen-Raum) verursachen können, sind immer noch zu wenige Menschen davor geschützt. Und das wird sich auch nicht von heute auf morgen ändern. Denn das Ziel der Weltgesundheitsorganisation (WHO), das Zervixkarzinom schnell, nämlich bis 2030, zu eliminieren sei „illusorisch", sagt Wiedermann-Schmidt. Apropos WHO. Die neue US-Regierung von Donald Trump hat den Ausstieg verkündet, was Experten wie Wiedermann-Schmidt große Sorgen bereitet: „Gerade das Impfprogramm in Amerika plus die sogenannte Surveillance von Infektionserkrankungen war ausgezeichnet und war immer federführend und vorbildgebend für die restliche Welt." Zum Welt-HPV-Tag gibt es für Mitarbeiter und Studenten der MedUni weiter die Gratis-Impfung. Kleiner Bonus: Die Impfpässe der Impflinge werden überprüft und nach Lücken durchforstet.

durée : 00:02:18 - Le billet sciences - De nouvelles données publiées par Santé publique France mardi révèlent une progression notable de la vaccination contre les papillomavirus, notamment chez les jeunes filles de 15 ans. La France reste cependant en retard par rapport à d'autres pays européens. Le dépistage régulier demeure essentiel.

MILANO (ITALPRESS) - Il Papillomavirus (HPV) può colpire anche gli uomini? Dove e come? Quali sono gli organi più vulnerabili all'attacco di uno o più ceppi di HPV? Quanto tempo impiega l'HPV a dare lesioni tumorali gravi? Come bisogna comportarsi con la nuova o il nuovo partner, se si è contratto l'HPV in passato? Anche gli uomini dovrebbero vaccinarsi? Nel sessantaduesimo numero di Focus Salute, format di Italpress, la professoressa Alessandra Graziottin, ginecologa e oncologa, risponde ai quesiti più frequenti in caso di infezioni da Papillomavirus nell'uomo.sat/gsl

MILANO (ITALPRESS) - Come può una donna capire se ha contratto l'infezione da Papillomavirus (HPV)? Quali organi sono più vulnerabili all'attacco di uno o più ceppi di HVP? Quanto tempo impiega il virus a dare lesioni tumorali gravi? Che cosa vuol dire che l'HPV-DNA test è positivo? Pap test: che cosa significano sigle misteriose come LSIL e HSIL? Nel sessantunesimo numero di Focus Salute, format di Italpress, la professoressa Alessandra Graziottin, ginecologa e oncologa, risponde ai quesiti più frequenti in caso di infezioni da Papillomavirus nella donna.sat/gsl

MILANO (ITALPRESS) - Vaccino anti Papillomavirus: come funziona? Perché è sicuro? Come viene preparato? Contro quali ceppi ci protegge? Perché è importante vaccinare i figli adolescenti, ragazze e ragazzi, contro gli HPV? E quando è giusto vaccinarsi anche da adulti? Nel sessantesimo numero di Focus Salute, format di Italpress, la professoressa Alessandra Graziottin, ginecologa e oncologa, spiega in modo semplice come viene preparato il vaccino anti HPV, come funziona, perché previene le infezioni da HPV non ancora contratti e perché può ridurre in parte l'aggressività di quelli da cui siamo già stati infettati. Saperne di più può aumentare la motivazione a vaccinare i nostri figli e a vaccinarci, se indicato, in serenità.sat/gsl

MILANO (ITALPRESS) - Che cos'è il Papillomavirus? E perché è un potente “bio-hacker”? Come fa a entrare nel nucleo delle nostre cellule, la centrale operativa che contiene il codice genetico (DNA)? Come fa ad “hackerarla” e obbligare poi la catena di montaggio cellulare (reticolo sarcoplasmatico) a costruire altri virus? Come può trasformare una cellula normale in cellula tumorale? Nel cinquantanovesimo numero di Focus Salute, format di Italpress, la professoressa Alessandra Graziottin, ginecologa e oncologa, analizza le caratteristiche dei Papillomavirus e la loro complessa capacità di aggressione.sat/gsl

La double vaccination des adolescents contre le papillomavirus et les infections à infections invasives à méningocoques est à l'étude dans le cadre du projet de budget de la Sécurité sociale. Mais en quoi sera-t-elle utile ?

Menslike papillomavirus is 'n algemene seksuele oordraaglike siekte in die land. Sekere stamme van die virus kan ernstige gesondheidsprobleme veroorsaak, insluitend servikale kanker. Inentingsprogramme, vroeë opsporing en veldtogte vir openbare gesondheid word geïmplementeer om die probleem aan te spreek. Die Kankervereniging van Namibië en die gesondheidsministerie sal die week gratis toetse uitvoer. Kosmos 94.1 Nuus het met Rolf Hansen, die uitvoerende hoof van die Kankervereniging, gesels.

MILANO (ITALPRESS) - Salute intima: la vulva è l'organo femminile più visibile eppure meno conosciuto e più trascurato. Quali sono i fattori biologici che la proteggono e la valorizzano? Che ruolo ha il microbioma vulvare, l'insieme dei microrganismi amici che la abita, nel mantenere un equilibrio ottimale (”eubiosi”) e proteggerla dalle infezioni? Perché la disbiosi del microbioma vulvare potenzia invece l'aggressività dei germi nemici, tra cui Papillomavirus ed Herpes virus? Perché è indispensabile anche nel mantenere il “profumo di donna” così prezioso per nutrire il desiderio proprio e del partner? Nel cinquantaduesimo numero di Focus salute, format di Italpress, Alessandra Graziottin, ginecologa e oncologa, analizza le componenti dello “scudo vulvare” , tra cui il prezioso microbioma, ricco di Lactobacillus Crispatus, nel mantenere salute e benessere intimo.fsc/gsl

durée : 00:03:23 - Le Dr Laurent Marié nous parle de la vaccination contre le Papillomavirus - La campagne de vaccination des élèves de 5ème contre le papillomavirus a débuté dans les différents collèges de la région Bourgogne Franche-Comté. L'objectif est est de faire mieux que l'an dernier où un peu moins de 20% des jeunes de 12 ans et plus ont été vaccinés

durée : 00:04:20 - La vaccination contre le papillomavirus avec le docteur Laurent Marié, conseiller médical à l'ARS Bourgogne Franche-Comté

Aujourd'hui dans « Patients » César Ancelle-Hansen, médecin généraliste et urgentiste chez Livi donne la parole à une experte : Léa Loriguet, Onco-hématologue au CHI de Créteil. Ensemble, ils vous disent tout sur le papillomavirus humain et ses risques associés, notamment sur les cancers de l'oropharynx. Pour aller plus loin : L'association AkumaL'association Demain sans HPVL'association NO TABOO Vous souhaitez écouter ou réécouter le témoignage de Max ? : https://smartlink.ausha.co/patients/cancer-de-la-gorge-et-papillomavirus Vous souffrez d'un HPV et vous souhaitez en parler avec un médecin généraliste ou spécialiste ? Nos médecins sont à votre écoute.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Comment réagit-on quand, lors d'un dîner en amoureux, une grosseur survient subitement dans le creux de son cou ? Comment faire face à la maladie quand on ne sait pas qu'elle peut aussi toucher les hommes ?Connus sous l'acronyme HPV, les papillomavirus humains regroupent 200 virus hautement contagieux. Si leur implication est connue dans le cancer du col de l'utérus, ils sont également associés à d'autres types de cancers touchant les deux sexes, notamment les cancers de la bouche et de la gorge.Aujourd'hui dans « Patients » on va parler d'un sujet qui touche 80% des adultes au cours de leur vie : le papillomavirus. Pour aller plus loin : L'association AkumaL'association Demain sans HPVL'association NO TABOO Vous pouvez suivre Max sur son compte Instagram : https://www.instagram.com/maxmaxradio/?hl=fr  Vous souffrez du papillomavirus et vous souhaitez en parler avec un médecin généraliste ou spécialiste ? Nos médecins sont à votre écoute.*Ce podcast recueille des témoignages personnels qui peuvent heurter votre sensibilité. Nous vous rappelons que ces récits représentent le vécu de nos invités et ne sont pas nécessairement représentatifs de notre point de vue. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

C'est quoi les papillomavirus / HPV ?

Au cœur de la nuit, les auditeurs se livrent en toute liberté aux oreilles attentives et bienveillantes de Valérie Darmon. Pas de jugements ni de tabous, une conversation franche, mais aussi des réponses aux questions que les auditeurs se posent. Un moment d'échange et de partage propice à la confidence pour repartir le cœur plus léger.

Nous sommes très heureux de vous annoncer que “Patients” revient très bientôt pour une saison 2 !On vous donne rendez-vous le 2 mai prochain pour découvrir 6 nouveaux patients aux parcours inspirants ! À très vite dans “Patients” saison 2 le podcast imaginé par Livi, et en attendant, prenez soin de vous !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Qu'est-ce que le HPV ou papillomavirus ?

Contre le papillomavirus : seule solution, la vaccination

Spesso, quando si parla di prevenzione dei tumori, si trascura il fatto che un vaccino efficace e sicuro contro diverse forme di cancro esiste ed è offerto gratuitamente dal nostro servizio sanitario. E' il vaccino contro il virus del papilloma umano, o papillomavirus (HPV). Il papillomavirus è la causa di uno dei più frequenti tumori femminili, il cancro del collo dell'utero, ma è anche responsabile di tumori molto aggressivi che possono colpire anche il maschio, come i tumori della zona testa-collo. E' poi responsabile delle verruche genitali, che già da sole basterebbero a raccomandarne l'uso. Eppure le coperture vaccinali contro il papillomavirus sono ancora insufficienti, anche se l'OMS ha lanciato una campagna internazionale per l'eliminazione del cancro del collo dell'utero attraverso la vaccinazione. In questa puntata del podcast raccontiamo come si sia arrivati alla scoperta che il papillomavirus causasse il cancro del collo dell'utero, partendo da una storia che parla di suore e conventi.

durée : 00:06:21 - franceinfo junior - Dans franceinfo junior, des adolescents posent leurs questions sur les papillomavirus et le vaccin pour lutter contre ces virus.

Je vous propose aujourd'hui de découvrir une nouvelle expérience de la maternité. Avec un utérus fragilisé par le papillomavirus diagnostiqué au même moment qu'une première grossesse, Natacha n'a jamais connu une suite de couche "classique" puisqu'avec trois accouchements différents, elle est toujours passée par la case prématurité. De l'unité kangourou à la réanimation néonat, nous revenons ensemble sur ces trois expériences uniques et stressantes. On parle également de violence obstétricale, de viol gynécologique et de surcharge des services de maternité, des sujets sensibles et malheureusement bien trop le reflet de la réalité et de l'actualité. Envie d'en savoir plus ou de participer à ton tour ? Rendez-vous sur Instagram : @balance_ton_accouchement et @hello_maman_off.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Papillomavirus : l'appel à la vaccination de Maxime Deschaeck dans l'émission diffusée le mardi 5 mars 2024 2024 à 19h sur France 5. Au programme : Le retour médiatique de Monica Lewinsky qui vingt-cinq ans après le “Monica gate” devient l'égérie d'une campagne pour appeler les Américains à voter en novembre prochain. Au programme également ce soir la crue de la Seine, la réapparition de Kate Middelton en pleine convalescence et le témoignage d'un jeune animateur de radio atteint d'un cancer et qui veut sensibiliser sur la nécessité du vaccin contre le papillomavirus… Tous les soirs, du lundi au vendredi à 19h sur France 5, Anne-Elisabeth Lemoine et toute son équipe accueillent celles et ceux qui font l'actualité du jour.

Nous profitons de cette journée de sensibilisation aux papillomavirus humains pour donner la parole à l'un de nos collègues de RTL2, Maxime Deschaeck, 40 ans, atteint d'un cancer à la gorge, cancer qui s'est développé à cause d'un papillomavirus. Ecoutez L'invité de RTL Midi du 04 mars 2024 avec Agnès Bonfillon et Eric Brunet.

Nous profitons de cette journée de sensibilisation aux papillomavirus humains pour donner la parole à l'un de nos collègues de RTL2, Maxime Deschaeck, 40 ans, atteint d'un cancer à la gorge, cancer qui s'est développé à cause d'un papillomavirus. Ecoutez L'invité de RTL Midi du 04 mars 2024 avec Agnès Bonfillon et Eric Brunet.

Au menu du 2 mars 2024 dans l'émission "Ça va Beaucoup Mieux" : * Sécheresse, talons fendillés, ongles cabossés, durillons, nos pieds sont soumis à rude épreuve tout au long de notre vie ! Comment reprendre ses pieds en main ? * Vous avez d'irrépressibles envies de sucre le soir ? Deux cuillères de poudre d'une plante diluée dans de l'eau vous couperons toute envie de sucre ! * Faire des "squats" est un exercice incontournable de renforcement musculaire ! Jambes, fesses, dos, genoux s'en trouvent renforcés ! Tous les samedis, retrouvez Flavie Flament en compagnie de Jimmy Mohamed dans l'émission "Ça va beaucoup mieux", votre nouveau magazine santé et bien-être.

1. Destination Santé – Emmanuel Ducreuzet : Contre les papillomavirus, un vaccin récompensé ; Face au variant Omicron, les tests antigéniques moins efficaces ? 2. Reflet d'actualité : 2022-06 - Chauvin, Jethro Camille Musique : In The Secret (I Wan

1. Destination Santé – Emmanuel Ducreuzet : Contre les papillomavirus, un vaccin récompensé ; Face au variant Omicron, les tests antigéniques moins efficaces ? 2. Reflet d'actualité : 2022-06 - Chauvin, Jethro Camille Musique : In The Secret (I Wan

Une mannequin indienne a simulé sa mort sur Instagram, dans une opération de communication destinée à sensibiliser sur le cancer du col de l'utérus. Le docteur Jimmy Mohamed rappelle l'importance de la vaccination contre les papillomavirus. Ecoutez Ca va beaucoup mieux avec Jimmy Mohamed du 05 février 2024 avec Jimmy Mohamed.

Ecoutez Un point, c'est tout ! du 08 janvier 2024 avec Alba Ventura.

durée : 00:33:37 - Le 18/20 · Le téléphone sonne - Selon les données de l'ANSM datant de fin octobre, seuls 2,5% des collégiens de 5e se sont fait vacciner contre les papillomavirus alors que la campagne gouvernementale a démarré en septembre. Comment expliquer cette faible couverture vaccinale ?

À la rentrée 2023, une vaste campagne de vaccination contre les infections à papillomavirus humains, les HPV, a été lancée dans environ 7000 collèges volontaires en France. Cette initiative propose gratuitement la vaccination à tous les élèves de 5ᵉ, âgés de 11 à 14 ans. Selon la Fondation contre le cancer, près de 80 % de la population sexuellement active est exposée au risque d'une ou plusieurs infections successives par le papillomavirus. La transmission se produit le plus fréquemment lors de rapports sexuels, et dans 60 % des cas, l'infection au papillomavirus survient au début de la vie sexuelle, souvent dès le plus jeune âge. C'est pourquoi il est préférable de se faire vacciner entre 11 et 14 ans, l'efficacité du vaccin est proche de 100% si elle est faite avant le commencement d'activités sexuelles. À quel âge peut-on se faire vacciner ? Pourquoi l'âge est-il limité ? Est-il possible de vacciner les garçons ? Un podcast Bababam Originals, écrit et réalisé par Joanne Bourdin À écouter aussi : Qu'est-ce que le "micro-cheating" ? Qu'est-ce que le vulturing, ce comportement toxique post-rupture ? Qu'est-ce que l'érosion du littoral ? Retrouvez tous les épisodes de "Maintenant vous savez". Suivez Bababam sur Instagram. Learn more about your ad choices. Visit megaphone.fm/adchoices

“On commence avec le lancement hier d'une double campagne de vaccination contre le Papillomavirus dans les collèges et contre le Covid 19 destinée en majorité aux personnes âgées, immunodéprimées, femmes enceintes ou professionnels de santé…”

durée : 00:05:13 - Avec sciences - par : Alexandra Delbot - Près de 80% de la population sera exposée au cours de sa vie aux HPV, des virus sexuellement transmissibles et responsables de certains cancers, notamment du col de l'utérus. Pour soigner ces lésions, un premier vaccin thérapeutique est en cours de développement.

Il est responsable de 6.000 cas de cancer chaque année en France, et pourtant, il existe un vaccin pour s'en protéger. Odile Pouget, spécialiste santé de RTL, vous explique tout sur le papillomavirus. Ecoutez L'invité de RTL Midi du 30 août 2023 avec Céline Landreau.

durée : 00:10:35 - La Question du jour - par : Julie Gacon - Un tiers des hommes de la planète est infecté par le papillomavirus, et la France ne fait pas figure de bon élève. Quelles conséquences sur la santé publique, notamment celle des femmes plus largement touchées par le cancer du col de l'utérus ? Cela alors même qu'une solution vaccinale existe. - invités : Isabelle Heard Gynécologue-obstétricienne, Centre national de référence du papillomavirus à l'Institut Pasteur

J'ai longtemps hésité sur le titre à donner à cet épisode tant il aborde de sujets essentiels. Je n'aime pas trop les titres à rallonge et les miens sont déjà trop souvent hors limite. Petite parenthèse, ce n'est pas l'excuse qui explique le retard de sortie de cet épisode, mais ça, je vous propose que nous en parlions en fin d'épisode. Revenons-en à l'épisode! J'aurais pu le titrer ainsi: aller au dela de ses limites pour assouvir son désir d'enfant. Oui mais j'ai trouvé que cette entête pouvait sonner comme culpabilisante et jugeante alors qu'en écoutant le témoignage de Tiphaine, nous aurions toustes eu envie de la soutenir et de la protéger. Qui n'a pas, un jour, dans son parcours, dépassé ses limites? Qui est resté sur sa ligne de conduite, alors qu'une épée de Damocles se profilait au dessus de sa tête? Cette contrainte peut être d'origine financière, humaine, ou tout autre. Dès lors qu'elle engage l'avenir du projet, son impact et sa résonance sur nos décisions sont énormes. Je pense que nous avons toustes des sujets avec lesquels nous sommes moins à l'aise dans nos parcours, qui parfois mènent à une nécessité de soin, physique ou mental. Tiphaine, que vous avez déjà entendu dans le podcast, nous raconte aujourd'hui son parcours de parentalité solo, accéléré par une santé fragile et un papillomavirus récidivant. Dans cet épisode, nous avons traité de nombreux sujets nécessitant une sensibilisation. Celui du Papillomavirus m'a semblé etre le plus indiqué à extraire et à mettre en avant, tant cette infection est méconnue et est engageante pour votre santé future et celle de vos enfants. Je vous laisse découvrir en quoi Tiphaine a dépassé ses limites, sous la pression de sa santé, et serait ravie de découvrir en quoi vous considérez avoir dépassé les votres. Pour cela, je vous proposer de me le raconter en commentaire du post Instagram sur le compte du podcast @lesenfantsvontbienpodcast. J'ajoute juste ici, que si ce podcast vous plait et que vous souhaitez le soutenir, je vous propose de nous retrouver sur ma page Steady. Vous en trouverez le lien en bio du compte Instagram du podcast: @lesenfantsvontbienpodcast et ici: https://steadyhq.com/les-enfants-vont-bienJe vous souhaite une bonne écoute. Soutenez ce podcast http://supporter.acast.com/lesenfantsvontbien. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Chaque année en France, 3000 femmes développent le cancer du col de l'utérus dû aux papillomavirus, une infection sexuellement transmissible que l'on pourrait largement éviter par la vaccination. Noémie a 35 ans et a découvert qu'elle en était atteinte au cours de sa première grossesse. Elle revient sur toute son histoire avec nous aujourd'hui. Le Dr Sophie Wylomanski, gynécologue obstétricien, est également avec nous pour répondre à nos questions sur les papillomavirus.

Avec Brahim NAÏT-BALK, retrouvez « Homomicro, le Podcast qui se prend aux mots », avec les invitées du jour: - Lou et Carole, organisateurices du collectif "Monts et merveilles" avec Nicolas RIVIDI - Pr Cécile BADOUAL "le Papillomavirus et les traitements / vaccin" avec Jean-François KERVIZIC et une question de Éric GARNIER Ainsi que le Cercle des Chroniqueurs: - Annabelle GUIRAUD  « Santé  pour Iel » sur le papillomavirus Réalisation/Montage: Nathan Hillaireau Soutenez-nous sur PayPal !

Chaque samedi, un résumé d'actu avec uniquement des bonnes nouvelles !

durée : 00:37:24 - Le téléphone sonne - Le 28 février, Emmanuel Macron annonce mettre en place à partir de la rentrée prochaine une campagne de vaccination contre les papillomavirus pour tous les élèves de 5ème. Responsable de plus de 6 000 cas de cancers par an, comment expliquer le retard de la France dans la prévention de ce virus ?

durée : 00:15:37 - Journal de 8 h - Emmanuel Macron doit "faire une annonce décisive" ce mardi pour "éradiquer le papillomavirus". Le virus est à l'origine de nombreux cancers. Constat d'une médecin spécialiste de la question, en début d'édition.

durée : 00:14:58 - Journal de 22h - Le chef de l'État a annoncé mardi la généralisation de la vaccination contre le papillomavirus dès la rentrée prochaine pour toutes les classes de 5e. Le papillomavirus provoque chaque année 6 000 cancers. Et seuls 23% des enfants de 11 à 14 ans sont vaccinés aujourd'hui. - invités : Saphia Guereschi infirmière scolaire et secrétaire générale du SNICS-FSU, le syndicat majoritaire des infirmiers de l'Éducation nationale

Eine Impfung, die potenziell Krebs verhindert. Das ist einmalig. Und dennoch haben wir in Deutschland eine miserable Impfquote, was HPV angeht. Ihr habt es euch mehrfach gewünscht, heute gehen wir es an: Wir sprechen über das humane Papillomavirus, auch HPV abgekürzt. Über das Risiko an Gebärmutterhalskrebs zu erkranken, wenn man HPV positiv ist. Über die Impfung, über monogame Beziehungen und diverse Konflikte, wenn die eine oder der eine auf einmal HPV positiv ist. Und wir sprechen darüber, wie es in Australien gerade läuft mit HPV, den Impfungen und den Abstrichen bei den gynäkologischen Praxen. Wie immer wissenschaftlich aber verständlich erklärt. #Frauenarzt #Gynäkologie Meine Kanäle für mehr wissenschaftlich, verständlichen erklärten Content zum Thema Frauengesundheit: Instagram: www.instagram.com/gynaeko.logisch/ YouTube: www.youtube.com/@gynaeko.logisch Meine Produkte und vieles mehr: www.richtigwissen.de/gynaekologisch

Vaccine development is a tremendous scientific breakthrough benefitting countless human lives. In Part 1 of this ASCO Oncology, Etc. Education Podcast episode, you will hear from the pioneering co-developer of the HPV vaccine Dr. Doug Lowy who serves as Principal Deputy Director of the National Cancer Institute , He speaks about how he got into the cancer field through the influence of his parents (4:49), the path that led him to focus on HPV (8:04), and his collaborative professional partnership with fellow HPV vaccine developer Dr. John Schiller (9:31). He also discusses his ongoing trial of one-dose administration, which promises to boost HPV vaccine uptake and reduce the burden of cervical cancer globally. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org. TRANSCRIPT Pat Loehrer: Hi, I'm Pat Loehrer. I'm Director of the Center of Global Oncology and Health Equity at Indiana University. Dave Johnson: I'm Dave Johnson. I'm a Professor of Medicine at UT Southwestern Medical Center in Dallas, Texas. Pat Loehrer: And this is Oncology, Etc. Dave, what have you been reading lately? Dave Johnson: Well, you and I have talked about a couple of books, but I thought in light of our guest today, I would mention a book I actually read probably nearly 60 years ago called The Microbe Hunters by Paul de Kruif - very interesting book, written, if memory serves me correctly, in the '30s, about many of the early bacteriologists and physicians who were interested in microbes; Pasteur, for example, and others. And I don't remember all the details, but it certainly was one that was influential for my choice of Medicine as a career, much like Arrowsmith. It was a really impactful book. I doubt many of our listeners today would've read that book, but if one is interested in the history of Medicine, it's a really interesting book to read. Pat Loehrer: You said 60 years ago. Okay, when I was reading books back then, it was about Dick and Jane. Dave Johnson: It's my understanding that you're not past Dick and Jane yet. Pat Loehrer: Good, good point. Good point. Well, it's such an incredible honor today, we have Dr. Doug Lowy as our interviewee today. Doug is the Principal Deputy Director of the National Cancer Institute and Chief of the Intramural Laboratory and Cellular Oncology Program at the Center for Cancer Research. He has served as Acting Director more than any other person - he served as Acting Director between April of 2015 and October of 2017, between April of 2019 and October of 2019, and most recently, he served as an Acting Director until Monday of this week, October 3rd. I had a chance of seeing Doug, I think, about a year ago, a week after he took over, and this is great to have that bookend here. He has had this title of Principal Deputy Director since July of 2010 and he leads many of the NCI's key scientific initiatives. He graduated from Amherst College, I think in Art History, I may be wrong on that, received his medical degree from New York University School of Medicine, trained in Internal Medicine at Stanford, and did a Dermatology Residency at Yale. His focus has been on papillomavirus and the regulation of normal and neoplastic growth. The papillomavirus is in close collaboration with Dr. John Schiller with whom he's co-authored 150 papers over the last 25 years. In the 1980s, he studied the genetic organization of papillomaviruses and identified oncogenes that were encoded by the virus, and he's been integrally involved and instrumental in the development of the papillomavirus vaccine. His laboratory did work with the RAS gene family and other suppressor genes, and as you can guess, he's just one heck of a smart guy. For his body of work and together with Dr. Schiller, they received the Federal Employee of the Year Award in 2007 and the Partnership for Public Service Award, the Dorothy P. Landon American Association for Cancer Research Prize for Translational Research, the Albert B. Sabin Gold Medal in 2011. In 2007, he got the Medal of Honor for basic research from the American Cancer Society, and President Obama awarded him the National Medal of Technology and Innovation in 2014. And in 2017, he received the Lasker-DeBakey Clinical Medical Research Award, which is considered one of the most prestigious honors in biomedical research. He is listed in the Institute of Scientific Information as one of the most highly-cited authors in Microbiology, and obviously, he's a member of the National Academy of Science and the National Academy of Medicine. Although these are notable honors, I'm told that none of them match the opportunity to speak with Dave and I today, and we really thank you so much, Dr. Lowy, for joining us. Thank you. Dr. Doug Lowy: Pat, I am speechless. Pat Loehrer: I so wish that Dave Johnson was, but could you tell us a little bit about your upbringing and your early life? Dr. Doug Lowy: Sure. I grew up in The Bronx, in New York City. I'm the younger of two boys. My brother is two and a half years older than I am. Both of my parents were general practitioners. My parents were both Americans, but my father had a classic sophomore slump when he was an undergraduate and was unable to get into a medical school in the United States. And so, he actually went to medical school in Austria, in the University of Vienna, and needed to learn German in order to go to medical school. But my parents were both very successful private practitioners. They had separate practices but practiced in the same office, and I learned about medicine, in large part, through them. They would go to lectures, and from the time I was probably nine or 10 years old, they would be telling me about cancer, and I became interested in that area. And then, when I was 16, my mother developed a deep melanoma on her leg, and so, cancer literally came home. And luckily, she had very good surgical treatment and lived for almost another 40 years - she lived until she was 80 and actually died of metastatic stomach cancer. But I got involved in thinking about cancer really through my parents. They talked with me about the role of tobacco in the development of lung cancer, and I heard about the Hammond and Horn report from the mid-1950s when it came out. Pat Loehrer: That was when Dave was reading the Microbe Hunters. Dr. Doug Lowy: I was reading it at about the same time. I must say that, although I found it very interesting, it didn't really speak to me, and now that's what I need to go and do. Although, in retrospect, that's what I've ended up going and doing. Pat Loehrer: Was it because of your mother that you had an interest in dermatology? How did you swing into there? Because we think of you mostly as a translational researcher. Dr. Doug Lowy: The dermatology was really when I was at NYU. I worked in the laboratory of Jan Vilcek, who had recently come from Czechoslovakia to NYU, and in his lab was Alvin Friedman-Kien, who was a dermatologist. And Alvin subsequently was among the first people to identify the AIDS epidemic through the Kaposi sarcoma. But Alvin talked with me about dermatology, and potentially, this might be an interesting field for me to go into. And then, when I went to Stanford, I did Internal Medicine for internship and a year of Medicine, and I did a rotation in Dermatology. And I was very impressed that the people who smiled the most were the dermatologists. And they had time also to think about what was going on with patients. And since I was at Stanford, it was a tertiary care facility and so we were taking care of people who were terribly sick, largely people with lymphoma and other types of cancer. And I thought that I might be better suited to taking care of people who were less sick than that. Dave Johnson: Is that where your interest in Papillomavirus started? Dr. Doug Lowy: Well, that was indirect. I first went into dermatology and then said, "Well, I want to be doing research. What can I do in research that might be connected both with dermatology as well as with cancer?" And the closest that I was able to come was Papillomaviruses. And when I started working on them, they were not yet clearly associated with cancer the way they are today. It was known that they were associated with an uncommon condition called Epidermodysplasia Verruciformis or EV and this is a condition where people have widespread HPV infection. And on sun-exposed areas, a subset of them develop skin cancer, but it's distinctly uncommon. The real interest, if you will, came from the identification of HPV infection and cervical cancer, which is one of the more common cancers, especially on a worldwide basis. And that was really the link with cancer. Pat Loehrer: You had an incredibly long-term collaboration with John Schiller, and as I mentioned, you published more than Dave and I have written letters to our wives with this man. Tell us a little bit about that relationship, that friendship, and that professional partnership. Dr. Doug Lowy: John, actually, he was at the University of Washington in Seattle doing his PhD, and it was so long ago that he sent me a letter, and I had been doing research on retroviruses. He sent me a proposal that he was doing his PhD in bacterial genetics, but he wanted to learn about mammalian viruses and so was writing to me about doing work with retroviruses. I wrote back to him and said, "That's very interesting, but I had just started working on papillomaviruses." And I thought the room for development and learning more was even greater there than with mouse retroviruses, which is what I was working on and what he was proposing to do some post-doctoral research on. Of course, he had never heard of papillomaviruses, so he had to look them up. But he developed a project with papillomaviruses and was able to get an NIH award to come as a postdoctoral fellow to work in my lab, and he actually did the research that he proposed, and it led to our improved understanding of the genetic organization of papillomaviruses. But then, it was clear that John and I got along very well, and it looked like both of us might be able to work together. So, he ended up getting tenure after he had been at NIH for about 10 years. And it's just been an amazing collaboration for me because John knows a lot of things that I don't know, and he thinks that I know some things that he doesn't know. And working together has been terrific, really, because when one of us doesn't want to do anything about something, the other one tends to step in. And so, it's been an amazing partnership that we have had for this time. Dave Johnson: This is really important. One of the reasons we agreed to do this podcast is to provide insight to up-and-coming faculty and fellows about mentoring and partnerships. What is the most important aspect of your partnership with Dr. Schiller? Dr. Doug Lowy: I think treating him as an equal colleague from day one, that probably is important. And then, since I was senior and he was junior, trying to make sure that he got credit when discoveries were made because the default, otherwise, was going to be that it was Doug Lowy who was doing things, whereas it was very clear that John was a key part of this collaboration. Dave Johnson: Now that your relationship is a long-lasting and mature one, how do you make those decisions now? Dr. Doug Lowy: Well, we've just worked together for a long time, and we enjoy talking, and actually, over the last few years, we are collaborating less rather than more. We're still very close colleagues, and we're in the same lab. But since I've been Deputy Director, especially during the last seven and a half years, I've been Acting Director for about three and a half out of the last seven and a half years, and there just isn't enough time to devote to the lab. And it would've been inappropriate for me to have been considered a co-principal investigator with John, who has gone off and done a lot of amazing research, more or less independent of me. Like everything else in this world, it develops, it continues to evolve, but we still are very close colleagues. As Pat was mentioning, this is my first week in several months not being Acting Director, and yesterday, John and I simply reveled in the opportunity to talk informally for 30 minutes without having to look at my watch because I needed to go someplace else. Dave Johnson: I'm glad you've reviewed that. I think a lot of junior faculty and fellows think that being in a leadership position is a cush job, and I'd tell them that it defies the laws of Physics because all poop flows uphill in this setting, and you have to deal with it. Pat Loehrer: I do want to spend some time talking about the NCI and your role there, but talk a little bit about how you have seen and where you envision that vaccines, particularly, HPV and maybe hepatitis vaccine - where you see it's been, and where it's going, and the impact that this potentially has on cancer worldwide? Dr. Doug Lowy: Well, one of the areas that John and I are continuing to work on closely is more research on the HPV vaccines. We noticed, quite a number of years ago, that the HPV vaccine performance was quite different from that of other so-called subunit vaccines. So, this is not an attenuated live vaccine, but instead is a subunit - it's just made up of one protein of the papillomavirus, the protein that gives rise to the outer shell of the virus. And what we noticed in a clinical trial that we were doing with colleagues in the intramural program, but who are medical epidemiologists - they are the leaders of the research, and what was happening was that although everyone was supposed to get three doses, there were some young women who were getting either two doses or one dose, in the trial, and this is in Costa Rica, where historically, cervical cancer has been the number one cancer of women. And it turned out that there was no difference in level of protection whether the women got one dose, two doses, or three doses. And even more surprising was that the antibody levels over the first few years were remarkably stable. And this led John and me to wonder whether it might be possible to get away with just a single vaccine dose. So, a lot of the research that we have been doing with our colleagues over the last few years is to develop stronger evidence that one dose of the vaccine would be sufficient to confer strong protection that's long-lasting. We've now carried out the studies in Costa Rica, with the initial trial to more than 10 years, and the antibody levels continue to be very stable, and the protection does not seem to have waned. Because this was not a pre-specified outcome, it's not enough to change standard of care. So, we and our colleagues are conducting a non-inferiority efficacy trial that is comparing two doses versus one dose of two different FDA-approved vaccines. One, GARDASIL 9, which is the HPV vaccine that's available for sale in the United States. But also Cervarix, which is made by GlaxoSmithKline, it's approved by the FDA, but it's no longer sold in the United States. And we anticipate that the results will read out in another couple of years. And if the results show that one dose and two doses are pretty comparable, we're expecting that this will lead to a worldwide change in recommendations for the HPV vaccine. So, whether you are in a high-income country or a low or middle-income country, that one dose is what will end up being recommended. Pat Loehrer: They could almost completely eradicate this disease, the most common cancer around the world. It's huge. Dr. Doug Lowy: So, Pat, the problem is that although the vaccine was approved 15 years ago, only about 10% of eligible young women in low and middle-income countries have actually been vaccinated up to now. And we think that the logistics and the cost of one dose could really be transformative, especially for those young women. It also would save the United States a great deal of money because needing only one dose would be far less expensive, and the government actually pays for about half of the HPV vaccine that is delivered to teenagers through the Vaccines for Children program.   Dave Johnson: Well, this concludes part one of our interview with Dr. Doug Lowy, Principal Deputy Director of the National Cancer Institute and Chief of the Intramural Laboratory of Cellular Oncology in the Center for Cancer Research. In the second part of this episode, Dr. Lowy will give his insight to vaccine hesitancy in the COVID era and the evolution of accomplishments over the past 50 years working at the National Cancer Institute. We want to thank all of our listeners for tuning in to Oncology, Etc. an ASCO Educational podcast, where we will talk about just about anything and everything. So, if you have an idea for a topic or a guest you would like for us to interview on the show, please email us at: education@asco.org.   Thank you for listening to the ASCO Education podcast. To stay up to date with the latest episodes, please click, Subscribe. Let us know what you think by leaving a review. For more information, visit the Comprehensive Education Center, at: education.asco.org. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement.    

The magical mythical "jackalope" is a essentially a horned rabbit, with antlers of different sizes and shapes. The jackalope is a mascot of the American West – inspiring an absolute river of trinkets and songs and whiskies and postcards and tall tales.Tale of the Jackalope

C'est un deux poids - deux mesures qui se confirme… Comme tous les autres réfugiés, les Ukrainiens ont bien du mal à pouvoir rentrer sur le territoire britannique. Alors que l'ensemble des pays européens ont mis en place une protection temporaire. Mesure d'exception qui permet non seulement l'accès au logement, mais aussi l'emploi, la scolarité et la santé, Londres maintient une position très restrictive, et impose des visas.  À la mi-avril, seuls 12 000 réfugiés ukrainiens avaient pu franchir la Manche, même si 42 000 visas ont été accordés. Certains pour les Ukrainiens qui ont de la famille ; et les autres pour ceux qui sont accueillis par des bénévoles.  Dans le sud de l'Angleterre, Marie Billon a rencontré une famille anglaise qui justement se bat contre toutes les difficultés administratives pour accueillir une famille ukrainienne.   L'ambiguïté du président serbe Le conflit en Ukraine pourrait aussi peser sur son prochain mandat présidentiel. Alexandar Vucic a été réélu à la tête de la Serbie, au début du mois, avec 60% des voix au premier tour, mais ce nationaliste proche de Vladimir Poutine, se présente aussi comme un pro-européen favorable à l'admission de son pays dans l'UE. Un grand écart pas facile à tenir sur le long terme et que nous explique Martin Chabal.     Pas ou peu de vaccins contre le virus HPV en Turquie  C'est un virus dont on parle trop peu... responsable de la plupart des cancers du col de l'utérus. Le HPV ou Papillomavirus humain. Un vaccin existe et il est recommandé pour les filles et les garçons âgés de 11 à 14 ans. Mais en Turquie, seule une minorité des adolescents a accès à ce vaccin… parce qu'il est trop cher et n'est pas remboursé. Le sujet est régulièrement évoqué au Parlement pour tenter de rendre ce vaccin gratuit et obligatoire. Et des particuliers intentent des procès dans ce sens à la sécurité sociale. À Istanbul, c'est un reportage d'Anne Andlauer.  Et en Grèce, pour la première fois depuis cette dernière rentrée scolaire, les cours d'éducation sexuelle sont obligatoires. Un impératif au vu des chiffres catastrophiques sur le taux d'avortement des très jeunes filles. À Athènes, Joël Bronner.  Et l'accès à l'avortement, reste encore très compliqué en Irlande du Nord. Presque trois ans après sa légalisation décidée par Londres, le gouvernement nord-irlandais traîne des pieds avec des conséquences dramatiques sur la santé des femmes, et des jeunes filles qui sont contraintes de se rendre en Angleterre pour avorter. Depuis  Dublin, les explications de Laura Taouchanov.     (Rediffusion du 12 avril 2022)      

This week's episode is all about canine papillomavirus. They aren't always obvious wart-like lesions in young dogs. Did you know there are inverted papillomas?  Pigmented plaque-like lesions in Pugs? Check out the podcast to take a little dive into this common virus.

TWiV discusses the situation with monkeypox, risk factors for SARS-CoV-2 infections of cats and dogs, and a lineage-tracing mouse model for studying papillomavirus infections. Hosts: Vincent Racaniello, Rich Condit, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox update (CDC) SARS-CoV-2 infection of cats and dogs (Emerg Inf Dis) Mouse papillomavirus identification (Vet Patrol) Mouse model for papillomavirus infection (eLife) Vincent interviews Harald zur Hausen (virology blog) Letters read on TWiV 907 Timestamps by Jolene. Thanks! Weekly Picks Brianne – Microbes Rule! at Liberty Science Center Rich – Artemis I update:  Mission diagram, mission in photos, launch dates Vincent – Eco-sustainable 3D printed house – Tecla Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

This Week: The Jackalope! Look, a weird bunny! Isn't he cute? Whether it's a rabbit with an unfortunate disease, a weird new style of taxidermy, or a massive statue at Wall Drug, the Jackalope is an iconic American symbol that speaks to the beauty and oddity of nature...wait, they aren't real??? Today, we cover the Jackalope, an adorable horned rabbit that Cas legitimately thought was real for many, many years. Today's topics: Only the weird animals eat lunchables; the states are fightinggg (over the Jackalope); beloved Pixar shorts and Scooby-Doo specials; deathbed cryptid confessions; taxidermy's big break; Papillomavirus doesn't fuck around; weird rabbits of the world; Jude gets gaslit by Alien Reddit; grain entrapment.

We get cartoony with imaginary creatures, infectious diseases, and desecrated animal corpses :) Join us as we attempt to profit off of the demise of a sweet little critter, pick on cryptozoologists, taxidermists and....Americans (Oh my! How blasphemous!) and share some useless unscientific and morbid information that is sure to destroy all our chances of collaborating ever again! ====================== Huge THANK YOU!!! to Lindsey for helping narrate our absurd nonsense and being so cool! Check out their podcast "Just Might Exist" HERE If you enjoy hoax animal nonsense, be sure to check out Lindsey's episode on the Missourium. ====================== Send us suggestions and comments to darwinsdeviations@gmail.com Outro sampled from "Sequence (Mystery and Terror) 3" by Francisco Sánchez (@fanchisanchez) at pixabay.com Sound effects obtained from https://www.zapsplat.com Image Credit Joris Hoefnagel, Public domain, via Wikimedia Commons (Episode image is heavily edited, the image owner reserves all rights to their image, and is not affiliated with our podcast) SOURCES: A LOT of Wikipedia articles City of Douglas Wyoming NY Times: Douglas Herrick, 82, Dies; Father of West's Jackalope Jackalopes of Wyoming – Myth or Reality? Fantastically Wrong: The Disturbing Reality That Spawned the Mythical Jackalope The World's Scariest Rabbit Lurks within the Smithsonian's Collection Escudero, Clara & Williams, Richard & Timm, Robert & Pérez-Tris, Javier & Benitez, Laura. (2015). A Century of Shope Papillomavirus in Museum Rabbit Specimens. PLoS ONE. 10. e0132172. 10.1371/journal.pone.0132172. Zimmer, C. (2011). A planet of viruses. Chicago: University of Chicago Press. Morrow, William (2013). The Big, Bad Book of Beasts: The World's Most Curious Creatures. ISBN 978-0062087454 Irwin, Ken. (2009). Storytelling: An Encyclopedia of Mythology and Folklore. Armonk, NY: Sharpe Reference 2008. , ISBN: 978 0 7656 8047 1